Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
SEC Accession No. 0001104659-17-007801
Filing Date
2017-02-09
Accepted
2017-02-09 16:01:44
Documents
9

Document Format Files

Seq Description Document Type Size
1 S-3/A a16-22161_1s3a.htm S-3/A 503844
2 EX-5.1 a16-22161_1ex5d1.htm EX-5.1 26613
3 EX-23.1 a16-22161_1ex23d1.htm EX-23.1 2457
4 EX-23.2 a16-22161_1ex23d2.htm EX-23.2 2171
5 GRAPHIC g221611bmi001.jpg GRAPHIC 2305
6 GRAPHIC g221611bmi002.gif GRAPHIC 5474
7 GRAPHIC g221611bei001.jpg GRAPHIC 2305
8 GRAPHIC g221611bwi001.jpg GRAPHIC 2305
9 GRAPHIC g221611bwi002.gif GRAPHIC 5474
  Complete submission text file 0001104659-17-007801.txt   561621
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3/A | Act: 33 | File No.: 333-214882 | Film No.: 17587513
SIC: 2835 In Vitro & In Vivo Diagnostic Substances